STK11 and non-small cell lung carcinoma: Cumulatively, These results indicate that our LC/MS approach could identify distinct metabolite characteristics between the three treatment groups, thus allowing us to explore the mechanism of metformin-induced anti-tumor immunity in STK11 mutant NSCLC that had been demonstrated in our previous study [16].